Filing Flows › Health Care › Orchestra BioMed Holdings (OBIO)
Orchestra BioMed Holdings (OBIO) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 10, 2026 · Orchestra BioMed Holdings (OBIO) Q2 2026 earnings results →
Q2 2026 Revenue down 90% year over year to $88K
Orchestra BioMed Holdings made $88K in Q2 2026 (-90% Y/Y). Operating margin n/m, net loss $23.8M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 10, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $88K in Q2 2026, down 89% year over year and down 20% from the previous quarter.
Operating costs exceeded revenue by $22.4M, an operating margin of -25404.5%. Total costs grew 11% against a revenue fall of 89%. The fastest-growing cost line was Research & development (+20%). The quarter ended with a net loss of $23.8M, wider than the previous quarter's $20.7M loss.
Operating cash flow was −$19.3M. Non-cash charges added back $96K of depreciation and amortization and $2.5M of share-based compensation. Working capital and other items added $1.8M. Capital expenditures of $254K exceeded it, leaving free cash flow of −$19.6M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 10, 2026 | $88K | -90% | n/m | −$23.8M | −$19.3M |
| Q1 2026 | 10-Q | May 12, 2026 | $110K | -87% | n/m | −$20.7M | −$22.2M |
| Q4 2025 | 10-K | Mar 12, 2026 | $30.9M | 122× | 21.8% | $6.2M | −$2.3M |
| Q3 2025 | 10-Q | Nov 10, 2025 | $861K | -13% | n/m | −$20.8M | −$14.6M |
| Q2 2025 | 10-Q | Aug 12, 2025 | $836K | +8% | n/m | −$19.4M | −$15.5M |
| Q1 2025 | 10-Q | May 12, 2025 | $868K | +40% | n/m | −$18.8M | −$16.6M |
| Q4 2024 | 10-K | Mar 31, 2025 | $253K | -3% | n/m | −$16.2M | −$13.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
About Orchestra BioMed Holdings
Our vision is to accelerate medical innovation to patients through risk-reward-sharing partnerships with leading medical device companies. We are a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. We are led by a highly accomplished, multidisciplinary management team and a board of directors with extensive experience in all phases of therapeutic device development. Our business was formed in 2018 by assembling a pipeline of multiple late-stage clinical product candidates originally developed by our founding team.
In its own words, from its 10-K, filed Mar 12, 2026.
Orchestra BioMed Holdings against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -90% against the peers' median +5%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| OBIO Orchestra BioMed Holdings | Q2 2026 | $88K | -90% | n/m |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Orchestra BioMed Holdings 10-Q on SEC EDGAR · CIK 1814114 · Surgical & Medical Instruments & Apparatus
13F: who owns OBIO and who is buying
More on OBIO
- How Orchestra BioMed Holdings makes money: revenue by segment
- Orchestra BioMed Holdings next earnings date and what analysts expect
- Orchestra BioMed Holdings stock forecast, price target and fair value
- Who owns Orchestra BioMed Holdings stock: holders, funds and Congress trades
- Orchestra BioMed Holdings recalls, complaints and regulation
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results